Skip to content
The Kids Research Institute Australia logo
Donate

Search

Showing results for "clinical trials"

sPLA2 study: Immune ontogeny and prediction, prevention and management of late-onset sepsis in very preterm infants

Tobias Strunk MD, PhD, FRACP Head, Neonatal Health tobias.strunk@thekids.org.au Head, Neonatal Health Clinical Professor Tobias Strunk is a

Early surveillance of infants and preschool children with cystic fibrosis

Sensitive and non-invasive surveillance tools are needed for the clinical management of infants and preschool children with cystic fibrosis (CF). The lung clearance index from the multiple breath washout and functional and morphological outcomes from magnetic resonance imaging provide promising alternatives to current gold standard techniques. Early detection and treatment of lung disease during this important period offers the opportunity to improve the quality of life for individuals with CF.

Consensus guidelines on the use of bisphosphonate therapy in children and adolescents

This evidence-based consensus guideline presents recommendations and discusses the graded evidence (using the GRADE system) for these recommendations.

Questions about COVID-19 and kids

With the number of COVID-19 infections in Western Australia continuing to grow – including confirmed cases in children – The Kids Research Institute Australia understands that our community is growing increasingly worried.

Walkers unite for diabetes

A record Perth crowd turned out for JDRF’s One Walk to raise much-needed funds for Type 1 Diabetes (T1D) research last month.

Financial incentives to motivate treatment for hepatitis C with direct acting antivirals among Australian adults

Untreated hepatitis C virus (HCV) infection can result in cirrhosis and hepatocellular cancer. Direct-acting antiviral (DAA) therapies are highly effective and have few side effects compared to older interferon-based therapy. Despite the Australian government providing subsidised and unrestricted access to DAA therapy for chronic HCV infection, uptake has not been sufficient to meet the global target of eliminating HCV as a public health threat by 2030.